What Does Forian (FORA) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
A specialist in healthcare big-data analytics, Forian has attracted a major re-rating of its corporate value following record-breaking revenue growth, a successful turnaround to profitability, and the confirmation of a 2026 take-private acquisition.
Subscribe🏢 What kind of company is Forian?
Forian (Forian Inc, FORA) is a leading healthcare data-analytics specialist founded in 2020 and headquartered in Newtown, Pennsylvania. Its core asset is a vast healthcare data repository built in compliance with HIPAA (the U.S. Department of Health and Human Services privacy regulation), which the company analyzes using AI to deliver solutions that help pharmaceutical companies optimize new-drug marketing and financial institutions make investment decisions in the healthcare sector. Through its subsidiary Kyber Data Science, Forian combines medical claims data with clinical data to provide advanced analytics services, and it leads the data-driven decision-making market as its core business.
How does it make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Healthcare Analytics (Information Services) | About 92% | Revenue from data licensing and analytics for pharmaceutical and biotech companies |
Driven by the expanding adoption of its healthcare data platform, Forian has delivered explosive year-over-year revenue growth of roughly 50%. It is on track to meet its annual revenue guidance of approximately $28 million to $30 million and, through improved operating efficiency, has established a quarterly net profit trend, completing a clear earnings turnaround. Its most recent annual revenue is approximately $30.1M.
📐 Market cap and company scale
Market capitalization stands at $67.8M, roughly About 0% of Samsung Electronics' market cap. The company has 50 people employees.
Forian's market capitalization is approximately $67.8M, roughly About 0% of Samsung Electronics' market cap. Approximately 50 people data scientists and engineers are partnering with global technology companies such as Databricks to build out an extensive medical network map, further strengthening the company's market dominance.
Here are a few rewriting options for "Forian outlook and share-price trend": 1. Simple and direct: "Forian: Company Outlook and Share Price" 2. More descriptive: "Forian Inc.: Stock Performance and Future Outlook" 3. Analytical focus: "Forian: Share Price Trends and Market Outlook" 4. Casual style: "Forian: Where the Stock is Headed" 5. Professional tone: "Forian: Equity Analysis and Forward Outlook" The best option depends on your specific use case. If you need a section header for an article or report, option 1 or 2 would work well. For a more engaging blog post, option 4 might suit better.Looking ahead, FORA's key growth drivers are its 'transition to a private company' and the further sophistication of its data-monetization model. In April 2026, the company signed a merger agreement to be acquired entirely for cash at $2.17 per share, marking a fresh inflection point. With the +34.6% metric trending sharply upward, maximizing operating efficiency after the take-private deal is expected to be the decisive turning point for realizing corporate value. Over the long term, the company aims to leap forward as the world's leading healthcare data hub, delivering the fastest and most accurate analysis of real-world evidence (RWE) from clinical settings.
⚔️ Key strengths and risks
Forian has emerged as a powerhouse in the healthcare big-data market, posting steep revenue growth and entering a value-realization phase through a major 2026 acquisition deal.
💪 Key Strengths
⚠️ Key Risks
🔄 Competitors and related (beneficiary) stocks
Major competitors include global healthcare-data leader IQVIA (IQV), healthcare analytics platform Veeva Systems (VEEV), and private data-analytics powerhouse Databricks. Forian also competes with FactSet (FDS) and MSCI for share of the healthcare-specialized data market within financial analytics.
✅ Investor checkpoints
Three key checkpoints every Forian investor should verify.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 🤝 Completion of the take-private merger | Confirm that the acquisition process, scheduled for mid-2026, is completed without disruption so that shareholder value is realized. | Stable |
| 📈 Adoption of new data products (Chartis™) | Watch whether sales volume of analytics solutions continues to grow through new distribution channels such as the Databricks Marketplace. | Moderate |
| 📉 Management of data licensing costs | Check that the company is efficiently controlling the cost of sourcing raw data through negotiations with data providers to maintain margins. | Stable |
Given that the acquisition has been confirmed, share-price volatility may be limited to a range near the deal price ($2.17), and investors should note the downside risk if unexpected events such as a merger collapse occur.
Forian is a company that sells 'the truth hidden within data.' Having earned recognition for its structural improvements and entered a major exit phase, it is a stock worth watching as it navigates both the growth of the healthcare analytics market and the realization of its corporate value.
Check Forian's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
1-Year Price Performance
Analyst Consensus
52-Week Price Range⚔️ Key strengths and risks
Forian has emerged as a powerhouse in the healthcare big-data market, posting steep revenue growth and entering a value-realization phase through a major 2026 acquisition deal.
💪 Key Strengths
⚠️ Key Risks
🔄 Competitors and related (beneficiary) stocks
Major competitors include global healthcare-data leader IQVIA (IQV), healthcare analytics platform Veeva Systems (VEEV), and private data-analytics powerhouse Databricks. Forian also competes with FactSet (FDS) and MSCI for share of the healthcare-specialized data market within financial analytics.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| IQV | IQVIA Holdings Inc | $257.30 | +0.1% | $42.4B | 31.9 | 6.9 | 23.01% | - |
| VEEV | Veeva Systems Inc | $260.98 | +0.1% | $42.3B | 42.9 | 5.7 | 14.42% | - |
 FDS | Factset Research Systems Inc | $262.93 | -5.8% | $9.4B | 17.3 | 4.6 | 27.03% | 1.71% |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| GOOGL | Alphabet Inc | $332.66 | +0.6% | $4.06T | 16.7 | 6.5 | 48.68% | 0.24% |
| MSFT | Microsoft Corp | $492.56 | +0.2% | $3.66T | 27.4 | 8.3 | 34.04% | 0.79% |
| MSTR | Strategy Inc | $128.56 | -3.1% | $49.4B | - | 1.6 | -63.56% | - |
✅ Investor checkpoints
Three key checkpoints every Forian investor should verify.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 🤝 Completion of the take-private merger | Confirm that the acquisition process, scheduled for mid-2026, is completed without disruption so that shareholder value is realized. | Stable |
| 📈 Adoption of new data products (Chartis™) | Watch whether sales volume of analytics solutions continues to grow through new distribution channels such as the Databricks Marketplace. | Moderate |
| 📉 Management of data licensing costs | Check that the company is efficiently controlling the cost of sourcing raw data through negotiations with data providers to maintain margins. | Stable |
Given that the acquisition has been confirmed, share-price volatility may be limited to a range near the deal price ($2.17), and investors should note the downside risk if unexpected events such as a merger collapse occur.
Forian is a company that sells 'the truth hidden within data.' Having earned recognition for its structural improvements and entered a major exit phase, it is a stock worth watching as it navigates both the growth of the healthcare analytics market and the realization of its corporate value.
Check Forian's real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free